Dr. William H. Moore, M.D.
Radiology (Body Imaging Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,873
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Body Imaging Physician primary
NY license 218194 -
Diagnostic Radiology Physician
NY license 218194
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
- Long Island Community Hospital Patchogue, NY
Medical groups
- New York University (6,134 clinicians)
- New York City Health and Hospitals Corporation (571 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,873
- Services billed
- 10,486
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 9,377 | 106 |
| Injection, gadobutrol, 0.1 ml | 1,982 | 24 |
| X-ray of chest, 2 views | 1,342 | 782 |
| Ct scan of chest without contrast | 1,211 | 658 |
| X-ray of chest, 1 view | 949 | 720 |
| Ct scan of chest with contrast | 349 | 185 |
| Ct scan of blood vessels of chest with contrast | 152 | 98 |
| Core needle biopsy of lung or center cavity of chest (mediastinum), accessed through skin | 129 | 123 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 104 | 103 |
| Low dose ct scan of chest for lung cancer screening | 71 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $32,334 in total to this clinician.
| Galvanize Therapeutics, Inc | $31,607 |
|---|---|
| AstraZeneca UK Limited | $403 |
| Bard Peripheral Vascular, Inc. | $325 |
| Consulting Fee | $32,228 |
|---|---|
| Food and Beverage | $107 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Galvanize Therapeutics, Inc Apr 10, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $8,250 |
| Galvanize Therapeutics, Inc Jan 7, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $8,000 |
| Galvanize Therapeutics, Inc Feb 25, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $7,500 |
| Galvanize Therapeutics, Inc Jul 17, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $4,500 |
| Galvanize Therapeutics, Inc Jan 29, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $1,500 |
| Galvanize Therapeutics, Inc Apr 10, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $1,000 |
| Galvanize Therapeutics, Inc Dec 22, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $750 |
| AstraZeneca UK Limited Aug 20, 2025 | Consulting Fee | $403 |
| Bard Peripheral Vascular, Inc. Apr 21, 2025 | Consulting Fee | $325 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $41,735 in research payments for these studies, mostly to the institutions running them.
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie Inc. · Active, not recruiting · NCT05029882 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo…
AstraZeneca UK Limited - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996 - A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Beigene, Ltd. · Completed · NCT03957590 - Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Beone Medicines (shanghai) Co. Ltd · Active, not recruiting · NCT04379635 - A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment…
AstraZeneca UK Limited - Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie Inc. · Active, not recruiting · NCT03539536 - Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.